Spruce Street Capital LP Makes New $34.59 Billion Investment in Dianthus Therapeutics, Inc. $DNTH

Spruce Street Capital LP acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 354,816 shares of the company’s stock, valued at approximately $34,587,464,000. Dianthus Therapeutics accounts for about 6.8% of Spruce Street Capital LP’s holdings, making the stock its 6th largest holding. Spruce Street Capital LP owned about 0.65% of Dianthus Therapeutics at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. PNC Financial Services Group Inc. raised its holdings in shares of Dianthus Therapeutics by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after purchasing an additional 139 shares during the last quarter. First Horizon Corp acquired a new position in Dianthus Therapeutics during the first quarter worth $32,000. Virtus Investment Advisers LLC grew its position in Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after purchasing an additional 416 shares in the last quarter. Royal Bank of Canada grew its position in Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after purchasing an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after buying an additional 618 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Wedbush upped their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $124.27.

Dianthus Therapeutics Stock Down 0.9%

DNTH opened at $110.07 on Tuesday. Dianthus Therapeutics, Inc. has a 12-month low of $22.81 and a 12-month high of $117.88. The business has a 50 day moving average of $101.30 and a 200-day moving average of $85.62. The stock has a market cap of $6.02 billion, a price-to-earnings ratio of -26.52 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. As a group, analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Adam M. Veness sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer directly owned 65,292 shares of the company’s stock, valued at $7,058,718.12. The trade was a 71.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 287,084 shares of company stock valued at $29,615,923. 3.02% of the stock is currently owned by insiders.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.